Are  ||| S:0 E:4 ||| VBP
soluble  ||| S:4 E:12 ||| JJ
IL-2  ||| S:12 E:17 ||| CD
receptor  ||| S:17 E:26 ||| NN
and  ||| S:26 E:30 ||| CC
IL-12p40  ||| S:30 E:39 ||| CD
levels  ||| S:39 E:46 ||| NNS
useful  ||| S:46 E:53 ||| JJ
markers  ||| S:53 E:61 ||| NN
for  ||| S:61 E:65 ||| IN
diagnosis  ||| S:65 E:75 ||| NN
of  ||| S:75 E:78 ||| IN
tuberculous  ||| S:78 E:90 ||| JJ
pleurisy ||| S:90 E:98 ||| NN
?  ||| S:98 E:100 ||| .
The  ||| S:100 E:104 ||| DT
differential  ||| S:104 E:117 ||| JJ
diagnostic  ||| S:117 E:128 ||| JJ
utilities  ||| S:128 E:138 ||| NNS
of  ||| S:138 E:141 ||| IN
the  ||| S:141 E:145 ||| DT
levels  ||| S:145 E:152 ||| NNS
of  ||| S:152 E:155 ||| IN
soluble  ||| S:155 E:163 ||| JJ
interleukin  ||| S:163 E:175 ||| NNS
( ||| S:175 E:176 ||| -LRB-
IL ||| S:176 E:178 ||| NNP
) ||| S:178 E:179 ||| -RRB-
-12p40  ||| S:179 E:186 ||| NNP
and  ||| S:186 E:190 ||| CC
the  ||| S:190 E:194 ||| DT
IL-2  ||| S:194 E:199 ||| JJ
receptor  ||| S:199 E:208 ||| NN
in  ||| S:208 E:211 ||| IN
sera  ||| S:211 E:216 ||| NN
and  ||| S:216 E:220 ||| CC
pleural  ||| S:220 E:228 ||| JJ
effusions  ||| S:228 E:238 ||| NN
were  ||| S:238 E:243 ||| VBD
evaluated  ||| S:243 E:253 ||| VBN
in  ||| S:253 E:256 ||| IN
patients  ||| S:256 E:265 ||| NNS
with  ||| S:265 E:270 ||| IN
exudative  ||| S:270 E:280 ||| JJ
pleural  ||| S:280 E:288 ||| JJ
effusions ||| S:288 E:297 ||| NN
.  ||| S:297 E:299 ||| .
We  ||| S:299 E:302 ||| PRP
enrolled  ||| S:302 E:311 ||| VBD
a  ||| S:311 E:313 ||| DT
total  ||| S:313 E:319 ||| NN
of  ||| S:319 E:322 ||| IN
120  ||| S:322 E:326 ||| CD
patients  ||| S:326 E:335 ||| NNS
with  ||| S:335 E:340 ||| IN
exudative  ||| S:340 E:350 ||| JJ
pleural  ||| S:350 E:358 ||| JJ
effusions ||| S:358 E:367 ||| NN
.  ||| S:367 E:369 ||| .
The  ||| S:369 E:373 ||| DT
clinical ||| S:373 E:381 ||| JJ
,  ||| S:381 E:383 ||| ,
radiological ||| S:383 E:395 ||| NN
,  ||| S:395 E:397 ||| ,
and  ||| S:397 E:401 ||| CC
histopathological  ||| S:401 E:419 ||| JJ
diagnoses  ||| S:419 E:429 ||| NN
were  ||| S:429 E:434 ||| VBD
tuberculous  ||| S:434 E:446 ||| JJ
pleurisy  ||| S:446 E:455 ||| NN
in  ||| S:455 E:458 ||| IN
52 ||| S:458 E:460 ||| CD
,  ||| S:460 E:462 ||| ,
malignant  ||| S:462 E:472 ||| JJ
pleurisy  ||| S:472 E:481 ||| NN
in  ||| S:481 E:484 ||| IN
39 ||| S:484 E:486 ||| CD
,  ||| S:486 E:488 ||| ,
and  ||| S:488 E:492 ||| CC
parapneumonic  ||| S:492 E:506 ||| JJ
effusions  ||| S:506 E:516 ||| NN
in  ||| S:516 E:519 ||| IN
29  ||| S:519 E:522 ||| CD
patients ||| S:522 E:530 ||| NNS
.  ||| S:530 E:532 ||| .
We  ||| S:532 E:535 ||| PRP
measured  ||| S:535 E:544 ||| VBD
serum  ||| S:544 E:550 ||| CD
IL-12p40  ||| S:550 E:559 ||| CD
and  ||| S:559 E:563 ||| CC
adenosine  ||| S:563 E:573 ||| JJ
deaminase  ||| S:573 E:583 ||| NNS
( ||| S:583 E:584 ||| -LRB-
ADA ||| S:584 E:587 ||| NNP
)  ||| S:587 E:589 ||| -RRB-
levels  ||| S:589 E:596 ||| NNS
in  ||| S:596 E:599 ||| IN
patients  ||| S:599 E:608 ||| NNS
with  ||| S:608 E:613 ||| IN
tuberculous  ||| S:613 E:625 ||| JJ
pleurisy  ||| S:625 E:634 ||| NN
and  ||| S:634 E:638 ||| CC
in  ||| S:638 E:641 ||| IN
a  ||| S:641 E:643 ||| DT
control  ||| S:643 E:651 ||| NN
group  ||| S:651 E:657 ||| NN
treated  ||| S:657 E:665 ||| VBN
for  ||| S:665 E:669 ||| IN
pleural  ||| S:669 E:677 ||| JJ
effusion  ||| S:677 E:686 ||| NN
to  ||| S:686 E:689 ||| TO
determine  ||| S:689 E:699 ||| VB
if  ||| S:699 E:702 ||| IN
such  ||| S:702 E:707 ||| JJ
levels  ||| S:707 E:714 ||| NNS
were  ||| S:714 E:719 ||| VBD
useful  ||| S:719 E:726 ||| JJ
in  ||| S:726 E:729 ||| IN
the  ||| S:729 E:733 ||| DT
diagnosis  ||| S:733 E:743 ||| NN
of  ||| S:743 E:746 ||| IN
pleural  ||| S:746 E:754 ||| JJ
effusion  ||| S:754 E:763 ||| NNS
( ||| S:763 E:764 ||| -LRB-
p  ||| S:764 E:766 ||| FW
< ||| S:766 E:768 ||| SYM
0.005 ||| S:768 E:773 ||| FW
) ||| S:773 E:774 ||| -RRB-
.  ||| S:774 E:776 ||| .
Definite  ||| S:776 E:785 ||| JJ
microbiological  ||| S:785 E:801 ||| NN
or  ||| S:801 E:804 ||| CC
histopathological  ||| S:804 E:822 ||| JJ
diagnoses  ||| S:822 E:832 ||| NN
of  ||| S:832 E:835 ||| IN
tuberculous  ||| S:835 E:847 ||| JJ
pleurisy  ||| S:847 E:856 ||| NN
or  ||| S:856 E:859 ||| CC
pleural  ||| S:859 E:867 ||| JJ
effusion  ||| S:867 E:876 ||| NN
were  ||| S:876 E:881 ||| VBD
recorded ||| S:881 E:889 ||| VBN
,  ||| S:889 E:891 ||| ,
and  ||| S:891 E:895 ||| CC
we  ||| S:895 E:898 ||| PRP
found  ||| S:898 E:904 ||| VBD
that  ||| S:904 E:909 ||| IN
ADA  ||| S:909 E:913 ||| NNP
and  ||| S:913 E:917 ||| CC
serum  ||| S:917 E:923 ||| JJ
soluble  ||| S:923 E:931 ||| JJ
IL-2  ||| S:931 E:936 ||| CD
receptor  ||| S:936 E:945 ||| NN
levels  ||| S:945 E:952 ||| NNS
aided  ||| S:952 E:958 ||| VBN
in  ||| S:958 E:961 ||| IN
diagnosis  ||| S:961 E:971 ||| NN
( ||| S:971 E:972 ||| -LRB-
p  ||| S:972 E:974 ||| FW
< ||| S:974 E:976 ||| SYM
0.001 ||| S:976 E:981 ||| FW
) ||| S:981 E:982 ||| -RRB-
.  ||| S:982 E:984 ||| .
The  ||| S:984 E:988 ||| DT
levels  ||| S:988 E:995 ||| NNS
of  ||| S:995 E:998 ||| IN
ADA  ||| S:998 E:1002 ||| NNP
and  ||| S:1002 E:1006 ||| CC
soluble  ||| S:1006 E:1014 ||| JJ
IL-2  ||| S:1014 E:1019 ||| NN
in  ||| S:1019 E:1022 ||| IN
pleural  ||| S:1022 E:1030 ||| FW
effusions  ||| S:1030 E:1040 ||| FW
afforded  ||| S:1040 E:1049 ||| FW
sensitivities  ||| S:1049 E:1063 ||| FW
and  ||| S:1063 E:1067 ||| CC
specificities  ||| S:1067 E:1081 ||| NN
of  ||| S:1081 E:1084 ||| IN
84.62 ||| S:1084 E:1089 ||| CD
%  ||| S:1089 E:1091 ||| NN
and  ||| S:1091 E:1095 ||| CC
82.69 ||| S:1095 E:1100 ||| CD
%  ||| S:1100 E:1102 ||| NN
and  ||| S:1102 E:1106 ||| CC
of  ||| S:1106 E:1109 ||| IN
70.59 ||| S:1109 E:1114 ||| CD
%  ||| S:1114 E:1116 ||| NN
and  ||| S:1116 E:1120 ||| CC
80.88 ||| S:1120 E:1125 ||| CD
% ||| S:1125 E:1126 ||| NN
,  ||| S:1126 E:1128 ||| ,
respectively ||| S:1128 E:1140 ||| RB
.  ||| S:1140 E:1142 ||| .
The  ||| S:1142 E:1146 ||| DT
soluble  ||| S:1146 E:1154 ||| JJ
IL-2  ||| S:1154 E:1159 ||| CD
receptor  ||| S:1159 E:1168 ||| NN
level  ||| S:1168 E:1174 ||| NN
afforded  ||| S:1174 E:1183 ||| VBN
a  ||| S:1183 E:1185 ||| DT
sensitivity  ||| S:1185 E:1197 ||| NN
and  ||| S:1197 E:1201 ||| CC
specificity  ||| S:1201 E:1213 ||| NN
of  ||| S:1213 E:1216 ||| IN
82.69 ||| S:1216 E:1221 ||| CD
%  ||| S:1221 E:1223 ||| NN
and  ||| S:1223 E:1227 ||| CC
52.9 ||| S:1227 E:1231 ||| CD
% ||| S:1231 E:1232 ||| NN
.  ||| S:1232 E:1234 ||| .
IL-12p40  ||| S:1234 E:1243 ||| NNP
levels  ||| S:1243 E:1250 ||| NNS
in  ||| S:1250 E:1253 ||| IN
pleural  ||| S:1253 E:1261 ||| JJ
effusions  ||| S:1261 E:1271 ||| NN
and  ||| S:1271 E:1275 ||| CC
sera  ||| S:1275 E:1280 ||| JJ
afforded  ||| S:1280 E:1289 ||| JJ
sensitivities  ||| S:1289 E:1303 ||| NNS
and  ||| S:1303 E:1307 ||| CC
specificities  ||| S:1307 E:1321 ||| NN
of  ||| S:1321 E:1324 ||| IN
80.77 ||| S:1324 E:1329 ||| CD
%  ||| S:1329 E:1331 ||| NN
and  ||| S:1331 E:1335 ||| CC
80.77 ||| S:1335 E:1340 ||| CD
%  ||| S:1340 E:1342 ||| NN
and  ||| S:1342 E:1346 ||| CC
of  ||| S:1346 E:1349 ||| IN
60.29 ||| S:1349 E:1354 ||| CD
%  ||| S:1354 E:1356 ||| NN
and  ||| S:1356 E:1360 ||| CC
39.71 ||| S:1360 E:1365 ||| CD
% ||| S:1365 E:1366 ||| NN
,  ||| S:1366 E:1368 ||| ,
respectively ||| S:1368 E:1380 ||| RB
.  ||| S:1380 E:1382 ||| .
Soluble  ||| S:1382 E:1390 ||| NNP
IL-2  ||| S:1390 E:1395 ||| NNP
receptor  ||| S:1395 E:1404 ||| NN
levels  ||| S:1404 E:1411 ||| NNS
in  ||| S:1411 E:1414 ||| IN
patients  ||| S:1414 E:1423 ||| NNS
with  ||| S:1423 E:1428 ||| IN
tuberculous  ||| S:1428 E:1440 ||| JJ
pleurisy  ||| S:1440 E:1449 ||| NNS
serve  ||| S:1449 E:1455 ||| VBP
as  ||| S:1455 E:1458 ||| RB
markers  ||| S:1458 E:1466 ||| VBN
of  ||| S:1466 E:1469 ||| IN
disease  ||| S:1469 E:1477 ||| NN
in  ||| S:1477 E:1480 ||| IN
non-endemic  ||| S:1480 E:1492 ||| JJ
countries ||| S:1492 E:1501 ||| NNS
,  ||| S:1501 E:1503 ||| ,
similarly  ||| S:1503 E:1513 ||| RB
to  ||| S:1513 E:1516 ||| TO
ADA  ||| S:1516 E:1520 ||| NNP
levels ||| S:1520 E:1526 ||| NNS
.  ||| S:1526 E:1528 ||| .
